Step therapy is one of the most widely used utilization management tools in employer-sponsored pharmacy benefits, and its impact on employer healthcare costs extends well beyond a simple reduction in the prescription drug line item. At its core, step therapy requires plan members to try clinically appropriate, lower-cost first-line medications before the plan will cover a more expensive, higher-tier alternative. When designed and administered thoughtfully, it can yield significant savings for self-funded employers while maintaining or even improving health outcomes. However, a poorly implemented program can shift costs to the medical side of the benefit and erode employee trust, creating hidden financial burdens for the organization.
Direct Cost Savings Through Pharmacy Spend Reduction
The most immediate and measurable effect of step therapy is a reduction in average wholesale price (AWP) costs per prescription. By steering utilization toward generic, biosimilar, or cost-effective brand medications as first-line therapy, employers reduce the per-claim cost of medications in high-spend therapeutic categories. These categories frequently include:
- Pharmacy benefit managers (PBMs) negotiate deeper discounts and rebates on preferred first-line agents, which flow back to the plan.
- Specialty drugs for autoimmune conditions (e.g., switching from a high-cost biologic to a biosimilar or methotrexate when clinically appropriate).
- Diabetes medications (e.g., requiring metformin before GLP-1 agonists).
- Mental health medications (e.g., requiring generic SSRIs before branded SNRIs).
For a mid-size employer with 5,000 covered lives, implementing evidence-based step therapy protocols can lower annual pharmacy spend by 5 to 12 percent, depending on the existing level of benefit design control and the therapeutic mix of the population. These savings are not just unit-cost savings; they also reduce the plan’s exposure to high-cost new-to-market drugs where long-term safety data may be limited, avoiding wasteful spending on medications that are no more effective than existing, less expensive alternatives.
Potential for Cost Shifting and Indirect Expense
While the pharmacy budget often declines, a narrow focus on step therapy without clinical nuance can inadvertently increase total healthcare costs. This phenomenon, known as cost shifting, occurs when patients who fail first-line therapy or cannot tolerate it experience delays in accessing effective treatment, leading to:
- Increased emergency department visits and hospitalizations for uncontrolled chronic conditions. For example, a rheumatoid arthritis patient stuck on a non-biologic agent for too long may develop irreversible joint damage requiring surgical intervention.
- Higher utilization of office visits, lab tests, and specialist consults as physicians navigate the step process and manage symptom flare-ups.
- Deteriorating mental health and productivity loss due to prolonged pain or disability, which can spike short-term disability claims and absenteeism.
An employer should always evaluate the total cost of care impact, not just the pharmacy silo. A comprehensive analysis often reveals that a $50,000 reduction in pharmacy spend can be offset by $75,000 in increased medical costs if the step therapy protocol is too rigid or lacks an efficient exception process. Therefore, the most mature benefits strategies pair step therapy with real-time clinical review and rapid prior authorization turnaround to prevent medically necessary delays.
Member Experience and Non-Adherence Risks
Step therapy can also drive costs upward through medication non-adherence. When employees and their families face multiple failed steps, cumbersome paperwork, or confusion about the process, they may simply abandon therapy. For chronic, asymptomatic conditions like hypertension or hyperlipidemia, non-adherence leads to catastrophic cardiovascular events years later. The employer then bears the cost of that heart attack or stroke-expenses that could have been avoided with more seamless access to an effective second-line agent.
Moreover, a frustrating step therapy experience damages the perceived value of the benefits package. In a tight labor market, a health plan that feels restrictive or burdensome can impact employee retention and recruitment, adding soft costs that are harder to quantify but just as real. Smart plan sponsors mitigate this by investing in clear communication, digital tools that guide members through the steps, and ombudsman services through their PBM or consultant that help members navigate exceptions quickly.
Compliance and Fiduciary Considerations Under ERISA
For self-funded employer plans governed by the Employee Retirement Income Security Act (ERISA), step therapy programs must be carefully constructed to meet fiduciary obligations. Plan fiduciaries must ensure that the program is designed solely in the interest of participants and beneficiaries, and that it does not create a discriminatory barrier to medically necessary care. Recent regulatory guidance and litigation have underscored the need for clinically sound, transparent step therapy criteria that are based on nationally recognized guidelines. Employers who fail to monitor their PBM’s step therapy protocols may face legal risk and associated costs, including settlement payments or corrective plan amendments. A robust governance process that includes regular review of step therapy metrics and member appeals data is a critical cost-containment mechanism in itself, ensuring the program continues to yield savings without harming covered individuals.
Maximizing Savings While Preserving Health Outcomes
To fully leverage step therapy as a cost-management tool, leading employers are evolving beyond simple, blanket "fail-first" mandates. They are implementing precision step therapy that accounts for:
- Genetic and biomarker-based criteria - Using lab results or prior treatment history to automatically exempt members who are unlikely to respond to the first-line agent, thus reducing trial-and-error costs.
- Integrated medical and pharmacy data - Triggering steps only when the patient’s diagnosis and comorbidity profile match the evidence. For instance, a plan might bypass step therapy for a diabetic with established cardiovascular disease and allow immediate use of an SGLT2 inhibitor with proven cardio-protective benefits.
- Rapid exception pathways - Guaranteeing a 24-hour review and response for step therapy override requests, often through an electronic prior authorization portal that integrates with the electronic health record.
- Member-centric incentives - Offering reduced copays for completing step therapy successfully or participating in disease management coaching alongside the protocol, which improves adherence and long-term health, further lowering total costs.
When employers monitor performance through a balanced scorecard that tracks net cost per member per month, medical cost trend, disability days, and member satisfaction, step therapy becomes a strategic lever that reduces total cost of care while maintaining a high-performing, healthy workforce.
The Bottom Line
Step therapy unequivocally reduces employer drug spend in the short term, but its true impact on overall healthcare costs depends entirely on program design, clinical oversight, and the employee experience. Plans that treat step therapy solely as a blunt cost-cutting tool risk expensive health deterioration and member dissatisfaction that eclipse pharmacy savings. Those that invest in evidence-based, flexible, and well-communicated protocols will find it to be a cornerstone of a sustainable, high-value benefits strategy-one that protects both the company’s bottom line and the well-being of its people.